Antiviral activity of Ellagic acid and Annona Muricata in cervical HPV related pre-neoplastic lesions: A randomized trial

- Ellagic acid and Annona Muricata have antiviral activity in vitro.
- In vivo anti-viral activity of Ellagic acid /Annona Muricata is investigated.
- Women with cervical HPV related preneoplastic lesion were randomly supplemented.
- Significant HPV clearance was obtained after 6 months.
- Tumor soppressor proteins expression in lesion thickness was stimulated.
- p21 expression significantly increased in lesion thickness.

Ellagic acid (EA) and Annona Muricata (AM) have antioxidant, anticarcinogenic and antiviral activity demonstrated by in vitro models. This pilot study investigated the in vivo potential anti-viral activity in women affected by Low squamous intraepithelial lesion (L-SIL) related to high risk human papilloma virus (HR-HPV), and the ability to modify the oncoproteins expression in the cervical lesion thickness. Sixty women affected by HR-HPV related L-SIL, were randomly divided into two groups: group A (n = 30) supplemented with EA (16 mg) + AM (100 mg) 2 times daily for 6 months and group B (n = 30) administered with placebo. HR-HPV clearance was obtained in 74% of cases in group A compared to 25% of cases in group B (p = 0.001) and p21 expression in LSIL thickness increased in 63.2% of cases in group A compared to 20% in group B (p = 0.03). AE/AM supplementation significantly induces HR-HPV elimination and stimulates p21 expression in LSIL thickness.